BDBM569233 US11427563, Compound 100::US11427563, Compound 114::US11427563, Compound 130::US11427563, Compound 134::US11427563, Compound 151

SMILES Cc1cncc2ccc(NC(=O)[C@@H]3CC3c3ccc(cc3)S(=O)(=O)Nc3ncccn3)cc12

InChI Key InChIKey=LUAWBDVVBXMLEL-UHFFFAOYSA-N

Data  35 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 35 hits for monomerid = 569233   

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 2nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 250nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 533nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 147nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 265nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 120nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 265nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 265nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 1nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 7.40nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 1nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 2nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 2nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 5nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 2.80nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 0.440nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 2.80nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 2.80nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 11nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 606nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 606nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 6nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 10nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 5nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 10nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 10nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 1nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 250nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 1nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 11nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 11nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 0.400nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 7.40nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 2.90nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 7.40nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent